A novel imaging biomarker for predicting early progression in glioblastoma multiforme

Takeaway

  • Chemical exchange saturation transfer (CEST) with multiparametric quantitative magnetic resonance imaging (qMRI) is a potential prognostic biomarker for patients with glioblastoma multiforme (GBM) undergoing chemoradiation (CRT).

Why this matters

  • GBM is the most common and aggressive primary malignant brain tumor, with poor overall progression-free survival rates. Identification of patients with GM who will progress early remains a challenge with clinical implications for treatment adaptation.

  • CEST is a novel image contrast for use with qMRI, and CEST at 3T and 7T have been suggested to predict response to therapy. However, the use of CEST at 1.5T would enable a broader use in MR-guided radiotherapy.

  • The results of this study indicate that the use of CEST at 1.5T is able to distinguish between tumor and contralateral normal-appearing white matter (cNAWM) as well as predict early progression, and warrants further investigation.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.